Article Figures & Data
Figures
- FIGURE 1.
Biodistribution and clearance of 211At-anti-CD45 mAb. (A) Radioactive content expressed as %IA/g ± SD (n = 3) in selected tissues from 2 dogs euthanized 19–22 h after injection. (B) Retention of 211At in blood for all treated dogs, determined by radioactivity measurements of repeated blood samples (%IA/g ± SD, 0.75 mg/kg, n = 5; 1.00 mg/kg, n = 3). p.i. = after injection.
- FIGURE 2.
Distribution of 211At in cryosectioned tissue samples imaged using iQID camera (A and B), and corresponding H&E-stained sections (C and D). A and C show lymph node sections from dog H638, biopsied 19 h after injection; B and D show sections of bone marrow core from dog H632, biopsied 2 h after injection. Green and yellow lines indicate lymph node follicles and paracortex (including visibly apoptotic areas), respectively, identified in H&E section. Overlaid with the α-image, outlined regions coincide well with low- and high-activity areas. Horizontal scale bars indicate 1 mm; color bars show 211At activity in microbecquerels.
- FIGURE 3.
Immunohistochemical staining of a formalin-fixed, paraffin-embedded lymph node from dog H629, biopsied 2 h after 211At-B10-CA12.10C12 injection. (A) H&E-stained section, including representative areas of cortex, paracortex, and medulla. B–D show staining for T cells (CD3), apoptosis (cleaved caspase-3), and macrophages (MAC 387), respectively, in corresponding areas of serially cut sections from the same lymph node. Scale bar represents 200 μm.
- FIGURE 4.
Dose rate images derived by 3-dimensional dosimetry using α-camera imaging. (A) Dose rate distribution at biopsy for dog H638 4 h after injection. (B) Corresponding H&E-stained section. (C and D) Dose rate distribution for dog H689 2 and 19 h after injection, respectively. Color bars express dose rate in mGy/h; scale bar (top right) indicates 1 mm.
Tables
Dog no. Age (mo) Weight (kg) mAb dose* (mg/kg) 211At activity (MBq/kg) Specific 211At activity (MBq/mg mAb) Autologous transplant Sample time (h after injection) Transfusions (d after HCT) Survival (wk) H573 12 7.7 0.75 14.6 19.5 No 22 — — H585 9 9.4 0.75 27.6 36.7 No 19 — — H543 20 12.8 0.75 11.5 15.3 Yes 19 7, 11, 19 48† H689 7 8.7 0.75 13.9 18.5 Yes 2, 19 7 32† H522 22 11.8 0.75 13.9 18.6 Yes 2 8 46† H629 8 9.5 1.00 14.6 14.6 Yes 2, 19 6, 8, 12 20‡ H638 10 12.3 1.00 18.4 18.4 Yes 4, 19 6, 10, 14, 16, 19, 22 32† H632 10 8.4 1.00 18.7 18.7 Yes 2, 19 7, 9 32† Bone marrow core Lymph node FMF CD45F FMF CD45F Dog no. 2–4 h 19–22 h 2–4 h 19–22 h 2–4 h 19–22 h 2–4 h 19–22 h H573* — 7,245 — 1,292 — 1,288 — 7,500 H585* — 1,009 — 213 — 402 — 7,027 H543* — 17,931 — 669 — 2,358 — 5,257 H689* 28,172 10,082 553 1,841 2,178 1,011 12,133 6,020 H522* 10,432 — 82 — 505 — 6,935 — H629† 17,956 1,000 109 65 758 2,774 6,041 6,025 H638† 37,176 32,831 220 548 1,780 1,057 15,113 13,754 H632† 24,298 38,886 155 564 1,517 4,478 14,112 17,067 Bone marrow core Lymph node FMF CD45F FMF CD45F Dog no. 2–4 h 19–22 h 2–4 h 19–22 h 2–4 h 19–22 h 2–4 h 19–22 h H573* — 44.7 — 51.0 — 9.9 — 97.0 H585* — 13.7 — 6.1 — 2.7 — 98.2 H543* — 94.2 — 15.2 — 17.2 — 82.4 H689* 95.8 81.7 11.7 87.8 8.0 10.0 93.7 96.8 H522* 91.4 — 0.4 — 4.2 — 97.0 — H629† 95.6 5.2 0.1 0.8 5.4 24.4 94.1 88.3 H638† 97.2 92.8 0.8 5.3 6.8 6.8 96.8 97.2 H632† 78.9 93.6 0.5 7.5 6.2 35.8 97.9 97.9
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy
- 211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
- Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
- Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated {alpha}-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival